|
|
NEW EVIDENCE
FOR
ANTI-OXIDANT PROPERTIES
OF VITAMIN C
Aristo Vojdani, Ph.D., M.T.a,b, Mohsen
Bazargan Ph.D.b, Elroy Vojdania
and Jonathan Wright, M.D.c
aImmunosciences Lab, Inc.
8730 Wilshire Blvd., Suite 305, Beverly Hills, California 90211
bDrew University School of Medicine and Science
Department
of Family Medicine, Los Angeles, CA 90059, USA
cTahoma Clinic - Kent, Washington
| Running title: |
Vitamin-C is an Anti-Oxidant |
|
|
| Key Words: |
Vitamin-C,
Anti-Oxidant, DNA Adducts, 8-Hydroxyguanosine, NK Cell Activity, Apoptosis, Cell Cycle
Analysis |
Correspondence and reprint requests to:
Aristo Vojdani, Ph.D., M.T.
Immunosciences Lab, Inc., 8730 Wilshire Blvd., Suite 305, Beverly Hills, CA 90211
Tel: (310) 657-1077 Fax: (310) 657-1053 e-mail: immunosci@ix.netcom.com
ABSTRACT
This study was designed to examine the effect of 500-5,000 mg of
ascorbic acid on DNA adducts, natural killer cell activity, programmed cell death and cell
cycle analysis of human peripheral blood leukocytes (PBL). According to our hypothesis, if
ascorbic acid is a pro-oxidant, then doses between 500-5,000 mg should enhance DNA adduct
formation, decrease immune function, change the cell cycle progression and increase the
rate of apoptosis. Twenty healthy volunteers were divided into four groups and given
either placebo or daily doses of 500, 1,000 or 5,000 mg of ascorbic acid for a period of
two weeks. On days 0, 1, 7, 15 and 21 blood was drawn, the leukocytes were separated and
then examined for intracellular levels of ascorbic acid, the level of 8-hydroxyguanosine,
NK cell activity, cell cycle progression and apoptosis. Depending on the subjects, between
0-40% increase in cellular absorption of ascorbic acid was observed when daily doses of
500 mg was used. At doses greater than 500 mg this cellular absorption was not increased
further and all doses produced equivalent increases in ascorbic acid on days 1-15. This
increase in cellular concentration of ascorbic acid resulted in a statistically no
meaningful changes in the level of 8-hydroxyguanosine, increased NK cytotoxic activity, a
reduced percentage of cells undergoing apoptosis and switched cell cycle phases from S and
G2/M to G0/G1. Following a period of one week, with no
placebo or vitamin washout, ascorbic acid levels along with functional assays, returned to
the baseline and became equivalent to placebos. In comparison with baseline values, there
was no change (not more than daily assays variation) in ascorbate concentrations or other
assays during oral placebo treatment. We conclude that ascorbic acid is an anti-oxidant
and doses up to 5,000 mg do not induce mutagenic lesions nor have negative effects on NK
cell activity, apoptosis or cell cycle.
I. INTRODUCTION
Ascorbic acid has been postulated as having anti-cancer activity1-8.
Indeed, in September 1990, a symposium sponsored by the National Institute of Health
extensively evaluated ascorbic acid's role in cancer prevention and possibilities in
therapy. The overall conclusion was that ascorbic acid has a protective effect for a
variety of human tumors4. A summary of this symposium goes into great detail on
the many different mechanisms of how ascorbic acid may have its protective and beneficial
effect4. An increasing body of evidence implicates the Natural Killer
phenomenon as a means of host defense against the growth and dissemination of tumor cells9-11.
NK cells have the ability to mediate natural resistance against tumors and may play an
important role in immune surveillance12-13. Therefore, factors enhancing or
influencing NK activity could be relevant for resistance to malignant disease. Based on
this rationale, the effect of ascorbic acid on human NK function in vivo was examined14.
It was reported that ascorbic acid enhanced NK cell function three- to ten-fold in healthy
control subjects. This enhancement was maximal 24 hours after administration of 60 mg/kg
of ascorbic acid orally14.
Many toxic chemicals are potential carcinogens, with the capability of
affecting NK cell numbers and function15-16. When NK function is studied after
exposure to a number of toxic chemicals, it is often decreased, both in animals15-22
and in humans23-26. Therefore, persistently low NK function as a result of
chemical exposure has been proposed as one possible mechanism for chemically-induced
carcinogenesis26,27. In view of this, ascorbic acid at 60 mg/kg body weight was
administered to patients exposed to toxic chemicals who demonstrated low NK cell activity
and abnormal T- and B-cell functions. Ascorbic acid in high oral doses was capable of
enhancing NK activity up to ten-fold in 78% of patients. Lymphocyte blastogenic responses
to T- and B-cell mitogens were restored to the normal level after use of ascorbic acid.
Signal transduction enzyme protein kinase C (PKC) appeared to be involved in the mechanism
of induction of NK activity by ascorbic acid. It was concluded that immune function
abnormalities could be restored by oral administration of ascorbic acid 28.
Despite this enhancement of immune function and the anti-cancer activity of ascorbic acid,1-8,14,28,
an increase of NK activity by ascorbic acid in animal models and in in-vitro systems is
not a generally observed phenomenon29,30. Moreover, a very recent study debates
its anti-oxidant or pro-oxidant activity.31 This debate was based on the
assessment of oxidative damage to peripheral blood lymphocytes after giving 500 mg per day
of ascorbic acid for six weeks to healthy volunteers. The level of 8-oxoguanine or
8-hydroxyguanosine was found to be decreased, whereas the level of 8-oxoadenine was
increased. This increase in a potentially mutagenic lesion, 8-oxoadenine, following a
typical ascorbic acid supplementation raised questions about the anti-oxidant nature of
ascorbic acid31. The recommended dietary allowance (RDA) for ascorbic acid is
60 mg daily, based on threshold urinary excretion of the vitamin and on preventing the
ascorbic acid deficiency disease Scurvy with a margin of safety32. Since other
factors such as steady-state plasma concentration, bioavailability and cell concentration,
play an important role, based on data from a more recent study and Institute of Medicine
criteria, it was recommended that the current RDA 60 mg should be increased to 200 mg
daily. Furthermore, it was concluded that safe doses of ascorbic acid are less than 1000
mg daily, and ascorbic acid doses above 400 mg have no evident value.33. We
decided to study the effect of 500 mg and much higher doses (up to 5,000 mg) of ascorbic
acid on DNA adducts, NK cell activity, and apoptosis of human PBLs. Studying NK cell
activity, programmed cell death and cell cycle phases, which involve signal transduction
pathways, along with markers of DNA damage relating to cellular absorption of ascorbic
acid, will better clarify the pro-oxidant and anti-oxidant properties of ascorbic acid.
II. MATERIALS AND METHODS
| A. |
Subjects and Ascorbic Acid Treatment
In this study, twenty healthy volunteers (12 females and 8 males aged
between 24-53) with no history of chronic diseases and with normal hematology, blood
chemistry and urinalysis were divided into four groups. Three females and two male
subjects were randomly assigned in each group. The first group was assigned placebos and
given 500 mg of calcium carbonate per day orally for two weeks. The experimental groups
were given 500 mg, or 6-10 mg/kg, 1,000 mg, or 11-20 mg/kg, 5,000 mg or 60-90 mg/kg of
ascorbic acid per day for the same period of time. Besides the calcium carbonate and oral
supplementation with ascorbic acid, none of the participants were taking vitamins. Blood
(30 ml) was drawn from each individual in a yellow top tube containing solution A (Beckton
Dickinson, Palo Alto, CA) for baseline studies of intracellular levels of ascorbic acid,
DNA adducts, NK cell activity, apoptosis and cell cycle analysis. After the first draw,
participants immediately ingested the ascorbic acid capsules. Exactly 24 hours, one week,
two weeks and three weeks (two weeks on ascorbic acid and one week on placebo) later,
blood was drawn again for the follow-up study. All subjects were followed by weekly
laboratory examinations, such as complete hematology with flow cytometry, blood chemistry,
and a urinalysis, including liver and kidney function tests. No abnormalities were
detected due to oral administration of ascorbic acid. |
| B. |
Preparation of Peripheral Blood Lymphocytes
Lymphocytes were prepared from
fresh heparinized peripheral venous blood by Ficoll-Hypaque density gradient
centrifugation (Litton Bionetics, Rockville, MD). Cells were washed three times with
Hanks' balanced salt solution (HBSS), and resuspended to a concentration of 10x106
cells/mL in a complete medium (CM) that consisted of RPMI-1640 supplemented with 10% fetal
calf serum and 1% antibiotics (100 U penicillin and 100 µg/ml streptomycin). Purity of
the cells was examined by flow cytometry using CD45/CD14 monoclonal antibodies and was
greater than 95%. Cells were used for different assays within an hour of isolation. |
| C. |
Measurement of Intracellular Level of Ascorbic Acid
After Ficoll-Hypaque separation,
PBLs were kept on ice and immediately sonicated for 10 seconds in 50 mM H3PO4
(pH 1.8) that contained 0.1 mM EDTA to minimize auto-oxidation. The pH of the resulting
extract was below 2.0. The extract was spun for 5 min. at 16,000 g at 4° C. An equal
volume of 200 mM potassium phosphate (pH 9.0) was added to the supernatant followed by
treatment with 10mM 2-Mercaptoethanol at 24° C. The commercial standard of ascorbic acid
was subjected to the same conditions as described above. Both the standards and sample
were used to determine intracellular levels by using the HPLC system (ESA Chemsford, MA)
Model 5600 coularray detector with solvent delivery pump model 580 and analytical cell
that makes use of two porous graphite electrodes. The column was B 3043-13 packed with
TSK-gel particles of 5µ size. The optimal mobile phase was 0.2M = KH2P04/H3P04
PH 3.0, delivered at 1 ml/min34. The detector's response to each
concentration of ascorbic acid was determined by making repeated injections of the
standards onto the chromatograph. Day to day variability of the quality control specimens
was less than 20%. |
| D. |
Measurement of DNA Adducts
DNA was isolated from PBLs by the
method described earlier35 with some modifications and used for measurement of
DNA adducts36. To the cell pellet, 250 µl of homogenizing buffer (pH 7.3)
containing 0.3 M sucrose, 0.025 M TRIS, and 0.002 M EDTA was added.
Residual RNA was destroyed by
adding 50µl RNase (1 mg/ml) to each sample, followed by incubation at 50° C for 30 min.
and then heated to 70° C for 10 min. The samples were then sonicated and 250 µl of
solution containing 1.0 M LiC1, 2 M urea, 0.04 M sodium citrate, 0.005 M disodium EDTA, 2%
sodium dodecyl sulfate (SDS) was added. 50 µl proteinase K (1 mg/ml) was added and
incubated at 50° C for approximately 1 hr., vortexing every 15 min. and 250 µl of
Chloroform-isoamyl alcohol (24:1) was added to each sample and shaken for 5 minutes, 3
consecutive times to extract the DNA. The aqueous layers were transferred to new tubes and
1/10 volume of 3M sodium acetate and 2 volumes of 95% ethanol were added. The samples were
placed in a freezer (-70° C) for 1 hr. and then centrifuged at 14,000 g for 20 minutes.
The alcohol was decanted and 1 ml of 70% ethanol was added to wash the DNA pellets. The
samples were centrifuged at 14,000 g for 10 minutes and the alcohol was decanted again.
Each sample was placed in a centrivap concentrator for 30 min. at 60° C. 250 µl of TE
(0.01 M Tris, 0.002 M EDTA pH7.4) was added to solubilize the DNA. The DNA was quantified
spectrophotometrically by measuring the absorbance at 260 and 280 nm. DNA digestion was
done by adding 25 µl of 0.5 M sodium acetate and 3 µl of 1M magnesium chloride to each
sample, incubating at 100° C for 5 min. They were immediately cooled on ice for 5 min. 10
µl of nuclease P1 (1 mg/ml) was added and then incubated for 1 hr. at 37° C.
This step was followed by the addition of 8 µl of 1M TRIS pH 8.5 was added to pH the
samples to 7.8. Then 2 µl of alkaline phosphatase (2 units) was added and the samples
were incubated for 1 hr. at 37° C. 4 µl of 5.8 M acetic acid was added to precipitate
the enzymes. The samples were then centrifuged at 14,000 g using DNA isolation spin
cartridges (GibcoBRL, Gaithersburg, MD), and were then ready for injection. The HPLC
system of ESA (Chemsford, MA) model 5600 coularray detector with solvent delivery pump
model 580 and YMC column (4.6 x 150mm) was used. The mobile phase consisted of 100 mM
sodium acetate in 5% methanol pH 5.2. The flow rate was set at 1.0 ml/min and ran for 15
min. Voltages were set at 150 mV, 450 mV for the detection of 2-deoxyguanosine (2dG), and
850 mV for detecting 8-hydroxyguanosine. The 2-Deoxyguanosine and all HPLC grade reagents
were purchased from Sigma Chemicals and 8-hydroxy-2'-deoxy-guanine (8OH2dTG) were
purchased from Wako Chemicals. Similar badge of standards and quality control materials
kept at -8° C were used for all HPLC assay. Day-to-day variability and reproducibility of
two different DNA adduct quality control material were less than 20%. If variation in our
quality control material as compared to the standards was 20% or higher, data was
rejected, columns and cells were washed, recalibrated and assays were repeated. |
| E. |
Natural Killer Cell Count
NK cell subset enumeration was
carried out by using lymphocytes from ascorbate-treated and non-treated individuals and
FACScan (Becton Dickinson, Palo Alto, CA). Mononuclear cell populations were determined by
two-color direct immunofluorescence and the use of whole-blood staining technique with the
appropriate monoclonal antibody and flow cytometry37. The fluorescein
isothiocyanate (FITC) or phycoerythrin (PE)-conjugated monoclonal antibodies (Becton
Dickinson) CD56 PE and CD3-FITC were selected for determination of the total NK cells and
NKHT3+/NKHT3- cells. To monitor lymphocyte markers, bit maps were
set on the lymphocyte population of the forward-angle light scatter versus a 90° light
scatter histogram. The percentage of positively stained cells for each marker pair, as
well as the percentage of doubly stained cells, was determined. Estimates of the absolute
numbers of lymphocyte positive for the respective surface markers were determined by
multiplying the peripheral lymphocyte cell count by the percentage of cells positive for
each surface marker. |
| F. |
Chromium51-release
Assay for Measuring NK Activity
A standard 4-hr 51Cr-release
assay was employed23. Briefly, 1 X 104 51Cr-labelled K562
tumor target cells in 0.1mL complete medium were added to different wells of a microtiter
plate. Effector cells were then pipetted into four wells to give effector:target (E:T)
ratios of 6:1, 12:1, 24:1 and 48:1. After a 4-hr. incubation at 37° C, the plates were
centrifuged at 1400 rpm for 5 min. and 0.1mL of supernatant from each well was collected
and placed in a gamma counter. The percentages of isotope released were calculated by the
following formula:
| % Lysis = |
Experimental Release -
Spontaneous Release |
X 100 |
Total Release - Spontaneous
Release |
Results
of NK cell assay for each effector/target ratio can be expressed as a percentage of the
specific lysis, but more commonly NK activity is expressed in terms of lytic units (LU).
To calculate the LU of NK activity, we used criteria established by Whiteside et al38
for a reproducible NK cell assay. For obtaining the LU of NK activity percentage of
specific lysis at all the measured effector target ratios is considered. First, the
effector target ratio yielding 20% lysis (E:T20) is estimated from these measurements. The
choice of 20% as a reference level of lysis was used arbitrarily by these investigators38.
However, it is quite commonly done and seems to be a good choice since experimental E:T
ratios can be chosen so that the calibration will rarely require extrapolation beyond the
range of experiment. The estimation of E:T20 is usually accomplished by fitting a curve to
the measured points on the graph of percentage of lysis versus E:T ratio and calibrating
the lytic unit.
One feature of LU, in
contrast with using the percentage of lysis at a single E:T ratio, is that four values at
four distinct ratios are used, generating more information and, therefore, greater
precision38. |
| G. |
Detection of apoptosis by flow cytometry
The rate of apoptosis was
determined by flow cytometry, utilizing the Apo-BRDU kit as described by the manufacturer
(Phoenix Diagnostics, San Diego, CA). Briefly, the large number of DNA strand breaks in
apoptotic cells results in a multitude of 3'-hydroxy termini DNA ends. In the presence of
terminal deoxynucleotidyl transferase (TdT), the 3'-termini of DNA can be labeled with
fluorescein tagged deoxyuridine triphosphate (F-dUTP). PBLs from different groups (1 to
2x106 cells) were cultured in RPMI-1640 supplemented with 10% fetal calf serum
(FCS) and 2% penicillin-streptomycin in 12-well plastic plates. The plates were incubated
for 12 hrs at 37° C in a humidified 5% C02 incubator. The cells were
harvested, centrifuged at 1000 x g for 5 min. at room temperature and washed twice with
PBS (5 ml per wash). Paraformaldehyde (1% w/v in PSB) was added to the cells, followed by
a 15 min. incubation on ice. The cells were pelleted and washed twice with PBS as
described above. The cells were fixed with ice-cold 70% ethanol and incubated at 20° C
overnight. The fixed cells, as well as positive and negative controls, were labeled by
adding 50 µl of DNA labeling solution containing 10 µl TdT reaction buffer, 0.75 µl TdT
enzyme 8 µl of Br-duTP and 32.25 µl of distilled water. The positive control was a
lymphocytic cell line treated with camptothecin39. Cells were incubated with
the DNA labeling solution for 60 min. at 37° C. At the end of the incubation time cells
were washed and resuspended in 0.1 ml of fluoresceinPRB-1 antibody solution in the dark
for 30 min. at R.T. After addition of 0.5 ml of propidium iodide/RNase A solution and 30
min. incubation cells were analyzed by flow cytometry. The day-to-day variability of the
assay was less than 20%. |
| H. |
Cell Cycle Analysis
Isolated PBLs were processed and
ethanol-fixed as described above. The fixed cells were prepared for cell cycle analysis.
Briefly, cells were resuspended in 100 µl of RNase A (Sigma)-PBS solution (180 µg
RNaseA/ml) and incubated at room temperature for 30 min. The RNase A solution was replaced
with 1 ml of PI solution (50 µg/ml in PBS with 0.1% Triton-X-100). PI staining was
performed for 15 min. at room temperature in the dark. Fluorescence measurements were
performed with FACScan (Becton-Dickinson) using the 488 nm line on an argon laser
operating at 15 mW. The data were collected into a two-parameter histogram showing light
scatter versus red fluorescence and were gated to eliminate any particles that were
not the correct size for intact cells.39. Similar to apoptosis,
sample-to-sample and day-to-day variation of this assay was less than 20%. |
| I. |
Statistical Analysis
SPSS software for Windows (Version
9.01[Feb. 1999]) was used to analyze the data. The Repeated Measures Analysis of Variance,
General Linear Model (GLM) was employed to examine the effect of different doses of
ascorbic acid (placebo, 500, 1,000, and 5,000 mg) on DNA adduct, NK cell activity and
programmed cell deaths. The GLM Repeated Measures procedure provides analysis of variance
between-subjects factors (placebo, 500-5,000 mg of ascorbic acid administration) and
within-subjects (day 0, days 1, 7, and 15 post ascorbic acid absorption, and day 21; one
week washout period). The statistical model included a full factorial model that contained
main effects and interaction effects. The "sums of the squares" were estimated
for a balanced model with no empty cells. The polynomial contrast was used to test for
differences among the levels of between-subjects factors. In addition, the Least
Significant Difference (LSD) test was employed to perform pairwise multiple comparisons.
The GLM Repeated Measure profile plots was employed to generate the plots for the
estimated marginal means of a given DNA adduct for each level of ascorbic acid absorption. |
III. RESULTS
| A. |
Intracellular Levels of Ascorbic Acid
Ascorbic acid absorption by
leukocytes at time 0 (pre-vitamin use), 1, 7, 15 days (post daily vitamin administration)
and one week after the last doses of 500, 1,000 and 5,000 mg is shown in Table I.
At all doses when 500-5,000 mg/day or 6-90 mg/kg body weight of ascorbic acid was used for
1, 7, or 15 days, an almost similar but significant increase (up to 90%) of cellular
absorption was observed. The repeated measure of analysis of variance for the placebo and
all three doses of ascorbic acid (500, 1,000, and 5,000 mg) on days 1, 7 and 15
post-vitamin use as compared to day 0 and day 21 (one week washout period) showed that
while differences within-subjects were statistically significant (F=5.6, P<.001), the
differences between-subjects were not significant (F=2.1 P=0.138), indicating a
significant but similar increase for all levels of ascorbic acid with a return to almost
baseline levels during the 7-day washout period (Figure 1). Therefore, while our data
shows clear time-dependent differences, no treatment-dependent differences were detected. |
| B. |
Levels of DNA Adducts
To assess the level of oxidative
damage to PBLs in terms of modified DNA bases, the level of 8-hydroxyguanosine was
measured (Table II). The results of the repeated measure of analysis of variance
for placebo and all three doses of ascorbic acid on days 1, 7 and 15 post-vitamin use as
compared to day 0 and day 21, showed that neither the differences within-subjects
(F=1.157;p=0.351), nor between-subjects, (F=0.4; P=0.748) were significant, indicating
that none of the ascorbic acid doses resulted in 8-hydroxyguanosine increase (Figure
2). However, the pairwise comparison analysis indicated rather a decrease in
8-hydroxyguanosine levels only at 1,000 mg ascorbic acid administration. |
| C. |
Natural Killer Cell Count
Flow cytometric analysis of NK cell
numbers were determined by FACScan using CD56 and CD3 monoclonal antibodies. The number of
natural killer cells (NKHT3+; NKHT3-) pre- and post-ascorbic acid
was within the standard variation of the laboratory and did not change significantly (more
than 10%). This insignificant change in the number of NK cells was consistent with our
earlier reports14,28. |
| D. |
Effects of Ascorbic Acid on NK Cell Activity
NK cell cytotoxic activity at time
0 (pre-vitamin use), 1, 7, 15 days (post daily vitamin administration) and one week after
the last doses of 500, 1,000 and 5,000 mg is shown in Table III. The repeated
measures analysis of variance detects an overall non-significant p-value associated with
within subjects and between-subjects effects. However, the pairwise comparison analysis
showed a significant increase in NK cell activity only at the level of 1,000 mg ascorbic
acid. These mixed results may stem from the small sample size accompanied with wide
variation in baselines level of NK Cell activity. Figure 3 clearly indicates that
subjects taking in 1,000 mg ascorbic acid gained elevation in NK activity one day after
oral administration of ascorbic acid (p <.01). Interestingly, the level of NK activity
returns to almost baseline seven days after washout period. |
| E. |
Effects of Ascorbic Acid on Apoptosis and Cell Cycle
Similar to NK activity, apoptosis
was performed on the baseline as well as placebo specimens and was compared to the
specimens after ascorbic acid administration. Results depicted in Table IV indicate
that 10 out of 15 subjects who consumed doses of 500 5,000 mg of ascorbic acid, had
significant decrease in the percent of cells going through programmed cell death. However,
the results of repeated measures of analysis provide mixed results. The tests of
within-subjects and between-subjects effects detect a statistically non-significant p
value of 0.06 and 0.84 for their respective interaction effects. But the pairwise
comparison analysis showed a significant decrease in apoptosis, at levels of 500 and 1000
mg ascorbic acid when days 1, 7 and 15 post-ascorbic acid administrations were compared to
day 0. These mixed results, again may stem from the small sample size accompanied with
wide variation in baselines level of apoptosis. These clear signs and indications of
decrease in apoptosis using 500 and 1,000 mg of ascorbic acid can be seen in Figure 4.
When ascorbic acid was not used for a week, this decrease in percent apoptosis was
returned to the baseline level. A decrease in the percentage of apoptotic cells by
ascorbic acid was accompanied by a change in the cell cycle as more cells shifted from S
and G2/M phases to G0/G1 phase (Table V). The
estimated marginal means of % S and G2/M phases of the cell cycle at 0-15 days
and one week washout period is shown in Figures 5 and 6. The most significant changes in
the %S and G2/M phases were observed with 500 and 1,000 mg doses of ascorbic
acid. The repeated measure of analysis variance showed that the differences
within-subjects are statistically significant. |
IV. DISCUSSION
A recent publication in Nature on pro-oxidant properties of
ascorbic acid raised many questions by the media and caused confusion in the public
whether to supplement their diet with ascorbic acid31. The report was based on
healthy volunteers who had dietary supplements of 500 mg of ascorbic acid per day for 6
weeks. The levels of oxidative damage on blood lymphocytes were measured in terms of
modified DNA bases. The level of 8-oxoguanine decreased, which is an indication of an
anti-oxidant capacity, but the level of 8-oxoadenine increased, which is an indication of
a pro-oxidant capacity of ascorbic acid31. Earlier in three different studies14,28,40
on healthy subjects as well as patients with low NK activity, ascorbic acid (60 mg/kg body
weight) enhanced NK cell activity significantly. This enhancement of NK cell activity by
ascorbic acid agreed with epidemiologic studies done earlier. Of the 46 such studies
conducted up to 1991 on non-hormone dependent cancer, a dietary ascorbic acid index was
calculated, and statistically significant protection was observed with high intake. This
conferred approximately two-fold protective effects compared with low intake2.
Therefore, it was of interest to clarify these points: first, whether
or not increase in ascorbic acid dose (oral use) results in increase in cellular
absorption? Second, if ascorbic acid is a pro-oxidant, then at doses of 500 mg or higher,
would it induce mutagenic lesions on DNA molecules and increase the level of
8-hydroxyguanosine? Third, will damage to DNA molecules result in decrease in the number
as well as the function of cells involved in the immune system? Fourth, what will be the
result of oxidative damage to DNA by ascorbic acid in relation to its subsequent effects
on apoptosis and cell cycle?
In the present study, we hypothesized that treatment with ascorbic acid
protects normal cells against apoptosis by activation of the anti-apoptotic gene (bcl-2),
reduction of oxidative damage and enhancement of immune function. To answer the question
of whether ascorbic acid, at doses of 500 mg or higher, is a pro-oxidant or an
anti-oxidant, in vivo, we measured cellular absorption of ascorbic acid in relation
to DNA damage, NK cell activity, apoptosis and cell cycle. Similar to an earlier study33
where cellular saturation was observed at 500 mg in a single dose, NK cell activity and
apoptosis plateaued at 1,000 mg, and no increase in 8-hydroxyguanosine was observed. Even
at the 5,000 mg/day or 60-90 mg/kg dose, 8-hydroxyguanosine and apoptosis were not
increased and NK activity was not reduced.
These results, along with many earlier reports strongly indicate that
ascorbic acid is an anti-oxidant1-14,28,40. While in our laboratory we did not
have the capability of measuring 8-oxoadenine by GC-MS as it was done by Podmore et al31,
we measured 8-hydroxyguanosine which is a superior marker of DNA damage. Using this
method, we established baseline values for 8-hydroxyguanosine lesions in human
lymphocytes. Mean values obtained were between 3.6 - 7.8 lesions per 106
guanine bases in non-smokers and between 8.5 - 33.5 lesions per 106 guanine
bases in smokers. These values of guanine lesions were different by a factor of ten based
upon the Podmore study31, which may be due to geographical variation in the
study subjects and/or methods used for DNA extraction. While these authors stated that
dietary supplements of 500 mg of ascorbic acid per day resulted in a significant decrease
in 8-oxoguanine levels, a significant increase in 8-oxoadenine levels was observed in the
DNA isolated from lymphocytes (P values in both cases were reported to be <0.01).
Following the 7-week washout period, levels of 8-oxoguanine and 8-oxoadenine returned to
those observed in the placebo. However, it was stated that the mean value obtained for
8-oxoguanine was 30 lesions per 105 guanine bases and 8 lesions per 105
adenine bases for 8-oxoadenine and that the decrease in 8-oxoguanine was identical to an
increase in 8-oxoadenine (P<0.01 in both cases). Since the net results are in favor of
decreased DNA adduct formation by 2.75 fold, the conclusion should have been that ascorbic
acid exhibits anti-oxidant properties and not that ascorbic acid exhibits pro-oxidant
properties31. We confirmed these anti-oxidant properties of ascorbic acid not
only by measuring DNA adducts and overall demonstrating no change in the number of DNA
lesions in white blood cells, but also by measuring the numbers and functionality of some
of these cells which did not decrease as well. Indeed, in the Podmore study31
no change was shown in either lymphocytes or neutrophil counts during ascorbic acid
treatment further confirming the anti-oxidant properties of ascorbic acid, since
pro-oxidants can induce structural alteration at the cellular level and push more cells to
go through apoptosis. The data presented in Table IV and Figure 4 clearly
demonstrates that ascorbic acid at doses of 500 and 1,000 mg reduced apoptosis by more
than 50% in individuals with moderately elevated baseline apoptosis. This is further
evidence to support the anti-oxidant properties of ascorbic acid, since oxidative stress
induced by pro-oxidants is a mediator of apoptosis and would not protect normal cells
against apoptosis as is shown in this study.
Several possible mechanisms of action for ascorbic acid in cancer
prevention have been described1-3,14,28,40-45. Ascorbic acid plays a major role
in free radical scavenging and protection against lipid peroxidation44,45.
Moreover, ascorbic acid and other anti-oxidants exert different effects on cancer and
normal cells.46 For example, high doses of different vitamins can induce direct
or indirect apoptosis in cancer cells while they can protect normal cells against
apoptosis.47 This protection of normal cells against apoptosis by vitamins is
in complete agreement with our findings.
The exact mechanism responsible for reduction of apoptosis by ascorbic
acid is not clear. Our preliminary study indicates an increase in bcl-2 mRNA expression in
the orally administered ascorbic acid groups (data not shown). A decrease in the
percentage of apoptotic cells by ascorbic acid correlated well with a reduction in the
percentage of cells in S and G2/M phases and their shift to G0/G1
phase. This shift in the cell cycle from S and G2/M to G0/G1
phase, along with a reduction in the percent of apoptosis, and enhancement in NK cell
activity are further support for the anti-oxidant properties of ascorbic acid. Since the
500 and 1,000 mg groups showed higher levels of cellular absorption and improved
functionality, further analysis with a larger sample size (which is the limitation of the
present study) is needed in order to obtain more statistically significant results.
Acknowledgment
The authors wish to thank professor Edwin
Cooper from The Laboratory of Comparative Immunology, Department of Neurobiology,
University of California, Los Angeles, for critically reviewing this manuscript.
Dr. Bazargan's contribution in this study was supported by a National
Institute of Health grant G12RR)-3026, the National Center for Research Resources
NIH/NCRR/RCMI.
REFERENCES
1. Hunter, D.F.; Manson, J.E.; Colditz, G.A. A prospective study of the
intake of vitamin C., E, and A and the risk of breast cancer. New England J. Med.
1993; 329:234-40.
2. Block, G. Vitamin C and cancer prevention: The epidemiologic
evidence. Clin. Nutr. 1991; 53:270-82.
3. Patterson, R.E.; White, E.; Kristal, A.R., et al. Vitamin
supplements and cancer risk: the epidemiologic evidence. Cancer Causes and Control
1997; 8:786-802.
4. Henson, D.E.; Block, G.; Levine, M. Ascorbic acid: biologic
functions and relation to cancer. J. Nat. Cancer Inst. 1991; 83-547-50.
5. Schlegel, J.U. Proposed uses of ascorbic acid in prevention of
bladder carcinoma. Ann. N.Y. Acad. Sci. 1975; 258:181-187.
7. Cameron, E.; Pauling, L. Supplemental ascorbate in the supportive
treatment of cancer; prolongation of survival times in terminal human cancer. Proc.
Nat. Acad. Sci. USA 1976; 73:3673-3685.
8. Slaga, T.J.; Bracken, W.M. The effects of anti-oxidants on skin
tumor initiation and aryl hydrocarbon hydroxylase. Cancer Res. 1977; 37:1631-1638.
9. Ghoneum, M.; Gill, G.; Wojdani, A., et al. Suppression of
basal and corynebacterium parvum-augmented NK activity during chemically induced tumor
development. International Journal Immunophar. 1987; 9:71-78.
10. Ghoneum, M.; Salem, F.; Gill, G., et al. NK cell activity
and tumor development of age-related variation to 3-methylcholanthrene. In: Ades, E.W. and
Lopes, G., eds. Natural Killer Cells and Host Defense. Basel:Karger 1989; 278-284.
11. Herberman, R.B. Possible role of natural killer cells in host
resistance against tumors and diseases. Clinical Immun. Allergy 1983; 3:479-485.
12. Jondal, M. The human NK cell-a short over-view and a hypothesis on
NK recognition. Clin. Exp. Immunol. 1987; 70
13. Roder, J.C.; Pross, H.F. The biology of human natural killer cell. J.
Clin. Immun. 1983; 2:249-263.
14. Vojdani, A.; Ghoneum, M. In vivo effect of ascorbic acid on
enhancement of natural killer cell activity. Nutrition Research 1993; 13:753-764.
15. Heidelberger, C. Chemical carcinogenesis. Ann. Rev. Biochem.
1975; 44:77-85.
16. Wojdani, A.; Alfred, L. Alterations in cell-mediated immune
functions induced in mouse splenic lymphocytes by polycyclic aromatic hydrocarbons. Cancer
Res. 1984; 44:942-945.
17. Vos, J.G.; Moore, J.A. Suppression of cellular immunity in rats and
mice by maternal treatment with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Int. Arch.
Allergy Appl. Immunol. 1974; 47:77-86.
18. Thor, D.E.; Reichert, D.F.; Flippen, J.H. The interaction of
chemical carcinogens and the immune response. J.R.E.S. 1977; 22:243-251.
19. Kalland, T.; Forsberg, J. Natural killer cell activity and tumor
susceptibility in female mice treated neonatally with diethylstilbestrol. Cancer Res.
1981; 41-:5134-5142.
20. Ehrlich, R.; Efrati, M.; Malatzky, E., et al. NK activity
and dimethylenzanthracene carcinogenesis. Int. J. Cancer 1983; 31:67-73.
21. Sharma, R.P.; Kociba, R.J.; Gehring, P.H. Immunotoxicologic effects
of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in rabbits. J. Environ. Pathol.
Toxicol. Oncol. 1984; 5:321-342.
22. Wojdani, A.; Attanzadeh, M.; Wold-Tsadik, G., et al.
Immunocytotoxicity by effects of polycyclic aromatic hydrocarbons on mouse lymphocytes. Toxicology
1984; 31:181-189.
23. Ghoneum, M.; Wojdani, A.; A.; Alfred, I.J. Effect of
methycholanthrene on human natural killer cell cytotoxicity and lymphokine production in
vitro. Immunopharmacology 1987; 14:27-33.
24. Ledesma, F.; Echevarria, S.; Casafont, F., et al. Natural
killer cell activity in alcoholic cirrhosis: Influence of nutrition. Eur. J. Clin.
Nutr. 1990; 4:733-740.
25. Vojdani, A.; Ghoneum, M.; Brautbar, N. Immune alteration associated
with exposure to toxic chemicals. Toxicol. Indus. Health 1992; 8:239-246.
26. Campbell, A.; Brautbar, N.; Vojdani, A. Suppressed natural killer
cell activity in patients with silicone breast implants: Reversal upon explanation. Toxicol.
Indus. Health 1994; 3:149-152.
27. Ben-Eliyahu, S.; Page, G.G.; Yirmiya, R., et al. Acute
alcohol intoxication suppresses natural killer cell activity and promotes tumor
metastasis. Nature Med. 1996; 2:457-462.
28. Heuser, G.; Vojdani, A. Enhancement of natural killer cell activity
and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals;
the role of protein kinase-C. Immunopharmacol. and Immunotoxicol. 1997; 19:291-312.
29. Siegel, B.V. Enhancement of interferon production by poly (rI),
poly (rC) in mouse cell cultures by ascorbic acid. Nature (Lond) 1975; 234:231-532.
30. Huwyler, T.; Hirt, A.; Morell, A. Effect of ascorbic acid on human
natural killer cells. Immunology Letters 1985; 10:173-176.
31. Podmore, I.D.; Griffiths, H.R.; Herbert, K.E. Vitamin C exhibits
pro-oxidant properties. Nature 1998; 392:559-560.
32. Sub-Committee on The 10th Edition of the RDA's Food and Nutrition
Board, Commission on Life Sciences, National Research Council (1989) Recommended Dietary
Allowances (National Academy Press, Washington, DC), 10th Ed., pp. 115-124.
33. Levine, M.; Conry-Cantilena, C.; Wangy, et al. Vitamin C
pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc.
Natl. Acad. Sci. 1996; 93:3704-3709.
34. Rose, R.C.; Bode, A.M. Analysis of water soluble anti-oxidants by
high-pressure liquid chromatography. Biochem. J. 1995; 306:101-105.
35. Kasai, H.; Nishimura, S.; Kurokawa, Y., et al. Oral
administration of the renal carcinogen, potassium bromate, specifically produces
8-hydroxydeoxyguanosine in rat target organ DNA. Carcinogenesis 1987; 8:1959-1961.
36. Park, J.W.; Cundy, K.C.; Ames, B.N. Detection of DNA adducts by
high-performance liquid chromatography with electrochemical detection. Carcinogenesis
1989; 10:827-835.
37. Fletcher, M.A.; Baron, G.C.; Ashman, M., et al. Use of whole
blood methods in assessment of immune parameters in immunodeficiency states. Diagn.
Clin. Immunol. 1987; 5:69-81.
38. Whiteside, T.L.; Bryant, J.; Day, R., et al. Natural killer
cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J.
Clin. Lab Anal. 1990; 4:102-110.
39. Vojdani, A.; Mordechai, G.; Brautbar, N. Abnormal apoptosis and
cell cycle progression in humans exposed to methyl tertiary-butylether and benzene
contaminating water. Human and Exp. Toxicol. 1997; 16:485-494.
40. Vojdani, A.; Namatalla, G. Enhancement of human natural killer
cytotoxic activity by vitamin C in pure and augmented formula. J. Nutri. and Environ.
Med. 1997; 7:187-195.
41. Levine, M. New concepts in the biology and biochemistry of ascorbic
acid. N. Engl. J. Med. 1986; 314:892-902.
42. Block, G.; Menkes, M. Ascorbic acid in cancer prevention. In: Moon,
T.E. and Micozzi, M.S., eds. Diet and cancer prevention. Investigating the role of
micronutrients. New York: Marcel Decker, Inc., 1989; 341-88.
43. Hanchk, A.B. Vitamin C and cancer. Prog. Clin. Biol. Res.
1988; 259:307-20.
44. Frei, B.; Stocker, R.; Ames, B.N. Anti-oxidant defenses and lipid
peroxidation in human blood plasma. Proc. Natl. Acad. Sci. USA 1988; 85-9748-52.
45. Frei, B.; England, L.; Ames, B.N. Ascorbate is an outstanding
anti-oxidant in human blood plasma. Proc. Natl. Acad. Sci. USA 1989; 86:6377-81.
46. Lehr, H.A.; Frei, B.; Arfors, K.E. Vitamin C prevents cigarette
smoke-induced leukocyte-aggregation and adhesion to endothelium in vivo. Proc. Natl.
Acad. Sci. 1994; 91:7688-92.
47. Prasad, K.N.; Edwards-Prasad, J.; Kumar, S., et al. Vitamins
regulate gene expression and induce differentiation and growth inhibition in cancer cells.
Their relevance in cancer prevention. Arch Otolaryngol Head Neck Surg. 1993;
119:1133-1140.
|
BACK |
 |
|
Test
results are for physician use only. |
|
|
COPYRIGHT (c)
2000 IMMUNOSCIENCES LAB., INC. ALL RIGHTS RESERVED.
|
|
|